Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.

por Sarah Huet, Pascale Cony-Makhoul, Maël Heiblig, Isabelle Tigaud, Sophie Gazzo, Amine Belhabri, Denis Souche, Mauricette Michallet, Jean-Pierre Magaud, Sandrine Hayette, Franck Nicolini
Publicado 2014

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells

por Marc G. Berger, Benjamin Lebecque, Thomas Tassin, Louis-Thomas Dannus, Juliette Berger, Mélanie Soucal, Agnès Guerci, Pascale Cony-Makhoul, Hyacinthe Johnson, Gabriel Etienne, Denis Guyotat, Marie-Claude Gagnieu, Bruno Pereira, Sandrine Saugues, Olivier Tournilhac, Eric Hermet, Céline Bourgne
Publicado 2021